VIP-targeted Cytotoxic Nanomedicine for Breast Cancer - Wikidata - awgldk - TriplyDB

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

http://www.wikidata.org/entity/Q36538910

about

Multifunctional polymeric micelles for delivery of drugs and siRNA.A new lipid-based nano formulation of vinorelbine Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer A novel peptide nanomedicine for treatment of pancreatogenic diabetes.Targeted Sterically Stabilized Phospholipid siRNA Nanomedicine for Hepatic and Renal Fibrosis.Solubilization of therapeutic agents in micellar nanomedicines.A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours.Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine.Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling.Vincristine and ɛ-viniferine-loaded PLGA-b-PEG nanoparticles: pharmaceutical characteristics, cellular uptake and cytotoxicity.

P2860

Q30438973-34696DA4-9605-4484-9086-698F55F050A3 Q34265212-0E3F9DB4-4DFB-4FFE-8C8C-A7B623C9752D Q36834005-889A677F-382C-4C7E-9A59-EA924D00DBA1 Q36875741-B5B32745-D022-49DE-9439-297E0481B028 Q37636279-E96CC9EB-4D57-4E2C-8728-81A575641ECA Q37654928-AE6E2058-5152-453F-962B-1A09B482EAF3 Q38733989-EB012642-7457-4EC1-B38F-EACCA6FD470E Q38849190-BEE1B0B9-9CA3-4E47-96BB-C25475C7661B Q41083994-EC8F44BE-CDB9-497D-8239-B3E4BDCDE75F Q51046952-55E3140F-CA08-4921-B400-9CC6281AAEC1

P2860

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

http://www.wikidata.org/entity/Q36538910

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@ast

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@en

type

label

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@ast

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@en

prefLabel

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@ast

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@en

P1433

Q36538910-90A3C2FB-0BE4-4A42-BE64-8FD4F7C16346

P1476

Q36538910-218BCBE8-58CF-4ED7-8BE4-884792AB97A3

P2093

Q36538910-0B98D087-A3E2-4E32-AA6D-2E9068A6BDAE

Q36538910-0DC1CC12-7CFB-408A-9758-55D0623EC495

Q36538910-20FA9DC7-43B5-465E-A13F-B2F0D956AE88

Q36538910-9F19BB01-8D0C-46D3-A019-6770D61B43B9

Q36538910-9F9F3DD5-00A7-42FC-A3FC-FD06F19F7BFE

P2860

Q36538910-006395B5-E3A9-4E41-A7AB-D6AE08CBDE76

Q36538910-028B7BC1-8774-465B-84F9-593F6A738B39

Q36538910-08D0BD39-3E55-4637-9C95-0BA50444DA0B

Q36538910-0A0ADD61-AC8C-40AA-A498-B665602DCC94

Q36538910-14E722E7-FB75-4838-AD5C-5F5A7742EF3B

Q36538910-162867BB-4A5E-46AC-B910-79A619D5026F

Q36538910-1953F45C-62CA-4282-87B9-F2BC79E59D99

Q36538910-29147716-A92E-4753-9FF8-5F6B623CFA80

Q36538910-2E005955-5356-4CD2-A142-F0A293130F1F

Q36538910-3D4ED2D3-2F76-4770-961A-1BEA76A5C886

P2888

Q36538910-F47908C5-959F-4EFC-ACA0-B5552FB2CDA8

P304

Q36538910-2B352DE3-CAE9-4727-B84B-E8C85A9FCBAB

P31

Q36538910-8E0B667F-6749-4B15-82DA-B8745F5F420E

P356

Q36538910-45A4F626-70F7-4680-B867-A335AABB96D0

P433

Q36538910-8EEC9DAF-A26C-4A45-94AA-D2D831878831

P478

Q36538910-B6768837-AC43-4340-A11E-1B61807418E7

P577

Q36538910-3610D28B-0F96-4B81-94C2-0E3167A4AB64

P698

Q36538910-4A7EE3F9-A136-47C0-88C2-1E4FC360DD04

P932

Q36538910-D7E8EBEF-C0E2-43F6-9D03-0FAE31CA389B

P356

S13346-012-0107-X

P1433

Drug delivery and translational research

P1476

VIP-targeted Cytotoxic Nanomedicine for Breast Cancer

@en

P2093

Antonina Kuzmis

http://www.w3.org/2001/XMLSchema#string

Aparna Dagar

http://www.w3.org/2001/XMLSchema#string

Hayat Onyuksel

http://www.w3.org/2001/XMLSchema#string

Israel Rubinstein

http://www.w3.org/2001/XMLSchema#string

Marin Sekosan

http://www.w3.org/2001/XMLSchema#string

P2860

Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin

In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications

Mechanism of taxane neurotoxicity

The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells

Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting.

VPAC receptor mediated tumor cell targeting by protamine based nanoparticles.

Folate-targeted drug strategies for the treatment of cancer.

Micellar nanomedicine of human neuropeptide Y.

Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery.

Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

P2888

s13346-012-0107-x

P304

454-462

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13346-012-0107-X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23336096

http://www.w3.org/2001/XMLSchema#string

P932

3546828

http://www.w3.org/2001/XMLSchema#string